1852-18-2

Usage

Uses

Used in Pharmaceutical Industry:
Tetrahydro-5-hydroxy-1H-pyrimidin-2-one is used as an intermediate in the biosynthesis of pyrimidine nucleotides for its potential role in the development of new drugs. Its presence in the biosynthetic pathway makes it a candidate for targeting specific metabolic processes in diseases.
Used in Anti-inflammatory Applications:
In the medical field, tetrahydro-5-hydroxy-1H-pyrimidin-2-one is utilized as an anti-inflammatory agent, leveraging its potential to modulate inflammatory responses, which could be beneficial in treating conditions where inflammation is a key factor.
Used in Antimicrobial Drug Development:
tetrahydro-5-hydroxy-1H-pyrimidin-2-one is also used in the development of new antimicrobial drugs, given its potential to target and combat microbial infections, offering a new avenue for treating resistant strains of bacteria.
Used in Therapeutic Research for Various Diseases:
Tetrahydro-5-hydroxy-1H-pyrimidin-2-one is employed in research for its potential therapeutic effects on a range of diseases such as cancer, diabetes, and cardiovascular diseases. Its multifaceted pharmacological profile positions it as a candidate for further exploration and development in medical treatments.
Further research and studies are essential to fully comprehend the potential medical applications of tetrahydro-5-hydroxy-1H-pyrimidin-2-one, ensuring its safe and effective use in various therapeutic areas.

InChI:InChI=1/C4H8N2O2/c7-3-1-5-4(8)6-2-3/h3,7H,1-2H2,(H2,5,6,8)

Upstream product

• 444-15-5 5-hydroxybarbituric acid 
• 99417-93-3 2-nitroamino-1,4,5,6-tetrahydro-pyrimidin-5-ol 
• 868-84-8 S,S-dimethyl dithiocarbonate 
• 616-29-5 1,3-Diamino-2-hydroxypropane 
• 105-58-8 Diethyl carbonate 
• 5807-14-7 1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine 

Downstream Products

• 917598-46-0 N,N'-dibenzyl-5-benzyloxytetrahydropyrimidin-2-one 
• 1355393-92-8 2-oxohexahydropyrimidin-5-yl 4-vinylbenzoate 
• 92397-66-5 tetrahydro-5-(tosyloxy)-2(1H)-pyrimidinone 

Relevant academic research and scientific papers

ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, MASK BLANK PROVIDED WITH ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PHOTOMASK, PATTERN FORMING METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, ELECTRONIC DEVICE, COMPOUND, AND METHOD FOR PRODUCING COMPOUND

The composition contains an alkali-soluble resin and a crosslinking agent that is represented by the following General Formula (I). In the formula, each of R1 and R6 independently represents a hydrogen atom or a hydrocarbon group having 5 or less carbon atoms; each of R2 and R5 independently represents an alkyl group, a cycloalkyl group, an aryl group, or an acyl group; and each of R3 and R4 independently represents a hydrogen atom or an organic group having 2 or more carbon atoms, and R3 and R4 may be bonded to each other to form a ring.

POLYMERIZABLE MONOMERS

A monomer of formula (1) is provided wherein R1 is hydrogen or a monovalent C1-C6 hydrocarbon group, and R2 is a group having polymerization functionality. Using the monomer, crosslinking units can be incorporated into a polymer chain. A chemically amplified negative resist composition comprising a base polymer having crosslinking units incorporated therein has a high sensitivity and forms a resist pattern with minimized LER.

Polymer, chemically amplified negative resist composition, and patterning process

A polymer is provided comprising recurring units having a N,N'-bis(alkoxymethyl)tetrahydropyrimidinone or N,N'-bis(hydroxymethyl)tetrahydropyrimidinone structure on a side chain. When a chemically amplified negative resist composition is formulated using the polymer and processed by lithography, a fine resist pattern can be formed with the advantages of improved LER and high resolution.

New AZT conjugates as potent anti-HIV agents

In an attempt to discover anti-HIV agents with much reduced cytotoxicity from the currently available HIV-reverse transcriptase inhibitors, AZT conjugates of cholanic acids, 2-imidazolidone-4-carboxylic acid and its derivatives, and N,N′-disubstituted 5-hydroxy-tetrahydropyrimidin-2-ones have been synthesized and their anti-HIV profiles determined with CEM-SS cell line. The AZT conjugates with 2-imidazolidone-4-carboxylic acid and 2-pyrrolidone-5-carboxylic acid through an ester linkage, and with N,N′-diphenyl-5-hydroxy-tetrahydropyrimidin-2-one through a succinate tether showed significantly higher therapeutic indexes than AZT while they also retained or enhanced AZT's anti-HIV activity. Thus, structural features that favor the desired therapeutic profile of the conjugates appear to include a five-membered ring cyclic urea or lactam, and six-membered ring cyclic urea with N,N′-diphenyl substitution. Copyright Taylor & Francis Group, LLC.